clinical trial · NCT06941857
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·recruiting·n = 20
Pancreatic CancerOxaliplatinIrinotecanFolinic Acid5-Fluorouracil (5-FU)NC410NivolumabIpilimumab
brief summary
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
started
Sep 4, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
May 5, 2026
official title
A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol